ARTICLE | Clinical News
OT-droperidol: Began Phase I testing
January 11, 1999 8:00 AM UTC
Anesta Corp. (NSTA), Salt Lake City, Utah Product: OT-droperidol Business: Neurological Therapeutic category: Neurotransmission Target: Dopamine-2 receptor Description: Dopamine-2 antagonist Indicati...